Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | SCC244 |
Synonyms | |
Therapy Description |
SCC244 (glumetinib) is an ATP-competitive inhibitor of MET, which may lead to cell-cycle arrest, decreased cell proliferation, and inhibition of tumor growth (PMID: 29237805). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
SCC244 | Glumetinib|SCC-244|SCC 244 | MET Inhibitor 59 | SCC244 (glumetinib) is an ATP-competitive inhibitor of MET, which may lead to cell-cycle arrest, decreased cell proliferation, and inhibition of tumor growth (PMID: 29237805). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04270591 | Phase Ib/II | SCC244 | Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer | Recruiting | USA | 2 |